BVS
Bioventus Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$13.32Close
$6.53 – $15.2652-week range
Nov 2, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 90 · stronger than 90% of stocks over 12 months
- Earnings growing EPS +334% year on year
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
13%
1wk
down 10.9%
price change
1mo
down 2.2%
price change
12-month return
up 97%
market up 11% ·
its own up 86%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
down 1%
year on year
EPS growth
up 334%
latest quarter
Sales growth
up 4%
latest quarter · -3 pts
ROE
up 14%
return on equity
Free cash margin
up 13%
$72.1M FCF
D/E
1.52
long-term debt / equity
Net debt / EBITDA
2.3×
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 10% ($0.3B → $0.3B)
Trade setup
ATR%
4.4%
$0.58 a day · 2×ATR $12.16
RS
90 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.4×
vs 50-day average
Up/down volume
0.94
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Revenue shrinking Revenue fell 0.9% over the year, from $573.3M to $568.1M.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+5% vs market2 sessions after results
Financials
- Gross 68%
- Net 4%
- Free cash 13%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $321.2M | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Gross margin | 73% | 70% | 65% | 64% | 68% | 68% |
| Operating income | $21.2M | $12.1M | -$167.2M | -$81.7M | -$15.2M | $54.0M |
| Net income | $16.4M | $19.4M | -$158.7M | -$156.2M | -$36.1M | $22.7M |
| Net margin | 5% | 4% | -31% | -30% | -6% | 4% |
| Earnings per share | — | $0.43 | -$2.59 | -$2.49 | -$0.56 | $0.33 |
| Free cash flow | $55.2M | $9.5M | -$15.0M | $8.0M | $37.8M | $72.1M |
| Free cash margin | 17% | 2% | -3% | 2% | 7% | 13% |
| Cash | $86.8M | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M |
| Long-term debt | $173.4M | $339.6M | $385.0M | $367.0M | $308.3M | $279.0M |
| Shareholders' equity | — | $458.9M | $325.2M | $173.6M | $147.9M | $184.1M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 27, 2026 | 39d |
| May 6, 2026 | Quarterly ↗ | Mar 28, 2026 | 39d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 4, 2025 | Quarterly ↗ | Sep 27, 2025 | 38d |
| Aug 6, 2025 | Quarterly ↗ | Jun 28, 2025 | 39d |
| May 6, 2025 | Quarterly ↗ | Mar 29, 2025 | 38d |
| Mar 11, 2025 | Annual ↗ | Dec 31, 2024 | 70d |
| Nov 5, 2024 | Quarterly ↗ | Sep 28, 2024 | 38d |
| Aug 6, 2024 | Quarterly ↗ | Jun 29, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 30, 2024 | 38d |
| Mar 12, 2024 | Annual ↗ | Dec 31, 2023 | 72d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results · Other events ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 21, 2026 | Regulation FD ↗ |
| May 6, 2026 | Results ↗ |
| Mar 5, 2026 | Results ↗ |
| Nov 17, 2025 | Director or officer change ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Aug 4, 2025 | Material agreement · New obligation ↗ |
| Jul 31, 2025 | Other events ↗ |
| Jun 4, 2025 | Shareholder vote ↗ |
| May 6, 2025 | Results ↗ |